Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
Cancer Medicine · 2024
DOI: 10.1002/cam4.70310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Benjamin J Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California Irvine Health, Orange, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Blastoid variant‐mantle cell lymphoma (BV‐MCL) represents an aggressive subset of patients with no established standard of care treatment approach.
Methods
We performed a retrospective analysis of the clinical characteristics and outcomes of 17 de novo BV‐MCL patients treated at our institution between May 2009 and September 2023. In addition, we reviewed the literature supporting 2nd/3rd generation Bruton's Tyrosine‐kinase (BTKi)‐based therapies for upfront management.
Results
The complete response rate to frontline and salvage therapy was 66.7% and 25%, respectively. Two‐year overall survival (OS) was low at 62.5% (95% CI, 34.7%–81.1%). Variables associated with higher OS included receipt of consolidative HSCT ( p = 0.017), TP53‐wild type ( p = 0.031), intermediate‐ versus high‐risk Mantle Cell Lymphoma Prognostic Index score ( p = 0.026), and achieving complete response with induction therapy ( p = 0.027).
Discussion
Treatment outcomes with chemo‐immunotherapy in BV‐MCL patients are poor, especially among TP53‐mutated patients. Recent findings describing positive outcomes with novel BTKi‐based therapies are encouraging and should be considered in this high‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of California Irvine Health, Orange, California, USA.
- Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, California, USA.
- Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
ORCID-Profile: Benjamin J Lee, Shawn P Griffin, Jean Doh, Stefan O Ciurea, Piyanuch Kongtim, Elizabeth A Brem
Förderung
- NCI NIH HHS
Zitieren
APA
Lee, B. J., Liu, J., Griffin, S. P., Doh, J., Ciurea, S. O., Kongtim, P., & Brem, E. A. (2024). Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies. Cancer Medicine. https://doi.org/10.1002/cam4.70310
Vancouver
Lee BJ, Liu J, Griffin SP, Doh J, Ciurea SO, Kongtim P, et al. Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies. Cancer Medicine. 2024. doi:10.1002/cam4.70310
BibTeX
@article{Lee2024,
author = {Lee, Benjamin J and Liu, Jenny and Griffin, Shawn P and Doh, Jean and Ciurea, Stefan O and Kongtim, Piyanuch and Brem, Elizabeth A},
title = {Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70310}
}
EUVIMED